The Lancet has published detailed results from the Phase III TACKLE study, showing the prophylactic benefits of Evusheld (tixagevimab/cilgavimab) in COVID-19.
In the outpatient treatment trial, the long-acting antibody combo showed statistically-significant levels of protection against progression to severe disease, leading to better outcomes.
Developed by British firm AstraZeneca (LSE: AZN), Evusheld is currently approved in the USA, the UK and the European Union to prevent disease caused by the novel coronavirus.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze